Portal de Periódicos da CAPES

Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate Cancer

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)64560-0

1527-3792

Roohollah Sharifi, Robert Browneller,

Hormonal and reproductive studies

No AccessJournal of UrologyCLINICAL UROLOGY: ORIGINAL ARTICLES1 Sep 2002Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate Cancer Roohollah Sharifi, Robert Browneller, and The Leuprolide Study Group† Roohollah SharifiRoohollah Sharifi , Robert BrownellerRobert Browneller , and The Leuprolide Study Group† View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64560-0AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The pattern of serum testosterone suppression as well as the potential for agonistic stimulation of serum testosterone during chronic treatment was compared in patients with prostate cancer randomized to receive 4 depot injections of either the monthly or 3-month depot formulations of leuprolide acetate in an open label study. Materials and Methods: A total of 71 patients were enrolled in a randomized prospective study comparing the pattern of serum testosterone suppression and the potential for agonistic stimulation of serum testosterone following reinjection (“acute-on-chronic” effect) during treatment of advanced stage prostate cancer with monthly (7.5 mg.) and 3-month (22.5 mg.) depot formulations of leuprolide acetate. Results: The 2 formulations produced nearly identical patterns of testosterone suppression which included uniform suppression throughout the duration of the dosing intervals. A transient minor “escape” from suppression (defined as a single testosterone value greater than 50 ng./dl. once suppression was achieved) occurred in 1 patient receiving each formulation. Assessment of agonistic stimulation (“acute-on-chronic” response) following the second depot injection as well as the depot injection following 3 months of treatment for each formulation revealed no pattern of stimulation. Conclusions: We conclude that monthly and 3-month sustained release (depot) formulations of leuprolide acetate provide consistent, uniform suppression of serum testosterone throughout the respective dosing intervals, and that the initial depot injection of each formulation provides sufficient pituitary desensitization to prevent agnostic stimulation of serum testosterone during chronic treatment. References 1 : Physiological basis for hormonal therapy in carcinoma of the prostate. Urol Clin N Amer1975; 2: 25. Google Scholar 2 : Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol1990; 143: 68. Link, Google Scholar 3 : Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer. Clin Ther1996; 18: 647. Google Scholar 4 : Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer. Urology1998; 51: 271. Google Scholar 5 : Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate. J Urol1984; 131: 1110. Link, Google Scholar 6 : Can combined DES LHRH depot therapy (ICI 118630) prevent endocrinologic clinical flare-up in metastatic prostate cancer?. Urology1988; 32: 37. Google Scholar 7 : Zoladex (ICI 118, 630): clinical trial of new luteinizing hormone-releasing hormone analog in metastatic prostatic carcinoma. Urology1987; 29: 185. Google Scholar 8 : Acute on chronic effect of depot Leuprolide in patients with stage D2 cancer of prostate. Anti-Cancer Drugs1990; 1: 29. Google Scholar From the Department of Urology, University of Illinois at Chicago, Chicago, and TAP Pharmaceutical Products Inc., Lake Forest, Illinois© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMorote J, Orsola A, Planas J, Trilla E, Raventós C, Cecchini L and Catalán R (2018) Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation TherapyJournal of Urology, VOL. 178, NO. 4, (1290-1295), Online publication date: 1-Oct-2007.OEFELEIN M (2018) Health Related Quality of Life Using Serum Testosterone as the Trigger to Re-Dose Long Acting Depot Luteinizing Hormone-Releasing Hormone Agonists in Patients with Prostate CancerJournal of Urology, VOL. 169, NO. 1, (251-255), Online publication date: 1-Jan-2003. Volume 168Issue 3September 2002Page: 1001-1004 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordstestosterone, leuprolideprostatic neoplasmsMetricsAuthor Information Roohollah Sharifi More articles by this author Robert Browneller More articles by this author The Leuprolide Study Group† Participants: Bruce Blank, Portland, Oregon; Stanley Brosman, Santa Monica, California; Donald Gleason, Tucson, Arizona; Mark Immergut, Rockville, Maryland; Joel Kaufman, Aurora, Colorado; Ira Klimberg, Ocala, Florida; Eugene Kramolowsky, Richmond, Virginia; Roohollah Sharifi, Chicago, Illinois; Christopher Steidle, Fort Wayne, Indiana; and Lamar Weems, Jackson, Mississippi. More articles by this author Expand All Advertisement PDF downloadLoading ...